{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:38:42Z","timestamp":1753875522288,"version":"3.41.2"},"reference-count":137,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Political Research Exchange"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/2474736x.2023.2193622","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T07:11:28Z","timestamp":1680160288000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Business as usual? How the pharmaceutical industry protected its long-term interests during and after eurozone bailouts (2011\u20132020)"],"prefix":"10.1080","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2584-4053","authenticated-orcid":false,"given":"Diogo","family":"Teixeira Pereira","sequence":"first","affiliation":[{"name":"NOVA SBE Health Economics & Management Knowledge Center, NOVA SBE, Universidade Nova de Lisboa, Carcavelos, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5405-1493","authenticated-orcid":false,"given":"Catherine","family":"Moury","sequence":"additional","affiliation":[{"name":"Department of Political Studies and Portuguese Institute of International Relations (IPRI), NOVA School of Social Sciences and Humanities, Universidade Nova de Lisboa, Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0881-4928","authenticated-orcid":false,"given":"Pedro","family":"Pita Barros","sequence":"additional","affiliation":[{"name":"NOVA School of Business and Economics, Nova SBE, Universidade Nova de Lisboa, Carcavelos, Portugal"}]}],"member":"301","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"e_1_3_3_2_1","unstructured":"Acordo bienal 2012\/2013 entre o Estado Portugu\u00eas e a Ind\u00fastria Farmac\u00eautica. 2012. Accessed November 30 2022. https:\/\/portalacordo.infarmed.pt\/Files\/Acordo_MS_APIFARMA_assinado_vf_2012.pdf."},{"key":"e_1_3_3_3_1","unstructured":"Acordo de 2014 entre o Estado Portugu\u00eas e a Ind\u00fastria Farmac\u00eautica. 2014. Accessed November 30 2022. https:\/\/portalacordo.infarmed.pt\/Files\/Acordo_Apifarma_2014_vass.pdf."},{"key":"e_1_3_3_4_1","unstructured":"Acordo de 2015 entre o Estado Portugu\u00eas e a Ind\u00fastria Farmac\u00eautica. 2014. Accessed November 30 2022. https:\/\/portalacordo.infarmed.pt\/Files\/Acordo_MF-MS-IF_2015_vf.pdf."},{"key":"e_1_3_3_5_1","unstructured":"Acordo trienal 2016-2018 entre o Estado Portugu\u00eas e a Ind\u00fastria Farmac\u00eautica. 2016. Accessed November 30 2022. https:\/\/portalacordo.infarmed.pt\/Files\/Acordo_APIFARMA_2016.pdf."},{"key":"e_1_3_3_6_1","unstructured":"Aditamento de 2013 ao acordo bienal 2012\/2013 entre o Estado Portugu\u00eas e a Ind\u00fastria Farmac\u00eautica. 2013. Accessed November 30 2022. https:\/\/portalacordo.infarmed.pt\/Files\/Aditamento%20APIFARMA_vass.pdf."},{"key":"e_1_3_3_7_1","unstructured":"Aditamento de 2017 ao acordo trienal 2016-2018 entre o Estado Portugu\u00eas e a Ind\u00fastria Farmac\u00eautica. 2017. Accessed November 30 2022. https:\/\/portalacordo.infarmed.pt\/Files\/Acordo_APIFARMA_Aditamento.pdf."},{"key":"e_1_3_3_8_1","unstructured":"Anexo II ao Acordo de 2015 entre o Estado Portugu\u00eas e a Ind\u00fastria Farmac\u00eautica. 2014."},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1041594"},{"key":"e_1_3_3_10_1","unstructured":"APIFARMA. 2012a. EFPIA alerta que Ind\u00fastria Farmac\u00eautica n\u00e3o pode ser \u2018alvo f\u00e1cil\u2019 de medidas de austeridade May 8. Accessed November 22 2022. https:\/\/www.apifarma.pt\/salaimprensa\/noticias\/Paginas\/EFPIAalertaqueInd\u00fastriaFarmac\u00eautican\u00e3opodeser\u201calvof\u00e1cil\u201ddemedidasdeausteridade.aspx."},{"key":"e_1_3_3_11_1","unstructured":"APIFARMA. 2012b. Medicamentos: Federa\u00e7\u00e3o Europeia defende solu\u00e7\u00e3o negociada entre governo e ind\u00fastria May 8. Accessed November 23 2022. https:\/\/www.apifarma.pt\/salaimprensa\/noticias\/Paginas\/MedicamentosFedera\u00e7\u00e3oeuropeiadefendesolu\u00e7\u00e3onegociadaentreGovernoeind\u00fastria.aspx."},{"key":"e_1_3_3_12_1","unstructured":"APIFARMA. 2018. The Pharmaceutical Industry in figures. Accessed November 22 2022. https:\/\/www.apifarma.pt\/wp-content\/uploads\/2021\/04\/IF_em_Numeros_2018.pdf."},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/spol.12480"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/1467-9299.00306"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1017\/jme.2021.5"},{"key":"e_1_3_3_16_1","unstructured":"Bank of Portugal. 2016. Analysis of Enterprises in the Pharmaceutical Sector. Banco de Portugal. Accessed November 22 2022. https:\/\/www.bportugal.pt\/sites\/default\/files\/anexos\/pdf-boletim\/study_cb_25_2016_en.pdf."},{"key":"e_1_3_3_17_1","unstructured":"Bank of Portugal. 2017. Profitability of Portuguese and European Enterprises. Banco de Portugal. Accessed November 22 2022. https:\/\/www.bportugal.pt\/sites\/default\/files\/anexos\/pdf-boletim\/study_cb_29_2017_en.pdf."},{"key":"e_1_3_3_18_1","volume-title":"Pharmaceutical Expenditure and Policies: Past Trends and Future Challenges","author":"Belloni A.","year":"2016","unstructured":"Belloni, A., D. Morgan, and V. Paris. 2016. Pharmaceutical Expenditure and Policies: Past Trends and Future Challenges. OECD."},{"key":"e_1_3_3_19_1","doi-asserted-by":"crossref","unstructured":"Bowen T. R. J. Chan O. Dube and N. S. Lambert. 2016. Reform Fatigue. Stanford University Graduate School of Business Research Paper No. 3394.","DOI":"10.2139\/ssrn.2736583"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/13608746.2019.1640966"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1017\/S004388712000009X"},{"key":"e_1_3_3_22_1","unstructured":"Buthe T. A. M. Jacobs E. Bleich R. Pekkanen M. Trachtenberg K. Cramer V. Shih S. E. Parkinson E. J. Wood and T. Pachirat. 2015. Transparency in Qualitative and Multi-Method Research: A Symposium."},{"key":"e_1_3_3_23_1","unstructured":"Campos A. 2017. Entrevista a Pedro Pita Barros: \u2018\u00c9 preciso que os or\u00e7amentos iniciais tenham compromissos realistas\u2019. Publico Online January 9. Accessed November 22 2022. https:\/\/www.publico.pt\/2017\/01\/09\/sociedade\/entrevista\/e-preciso-que-orcamentos-iniciais-tenham-compromissos-realistas-1757477."},{"key":"e_1_3_3_24_1","unstructured":"Cardoso D. C. Moury A. P. Costa and M. Escada. 2021. Governar para as pr\u00f3ximas gera\u00e7\u00f5es: Sucessos e fracassos de pol\u00edticas de longo prazo em Portugal (1995-2019). Almedina."},{"key":"e_1_3_3_25_1","doi-asserted-by":"crossref","unstructured":"Carone G. C. Schwierz and A. Xavier. 2012. Cost-Containment policies in public pharmaceutical spending in the EU (Economic Papers No. 461). European Commission.","DOI":"10.2139\/ssrn.2161803"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/13501763.2015.1115534"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-0343.2007.00328.x"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/0032329216656840"},{"key":"e_1_3_3_29_1","unstructured":"Corporate Europe. 2021. Big Pharma\u2019s lobbying firepower in Brussels: At least \u20ac36 million a year (and likely far more). Corporate Europe Observatory May 31."},{"key":"e_1_3_3_30_1","unstructured":"Criteri e modalita\u2019 con cui l\u2019Agenzia italiana del farmaco determina mediante negoziazione i prezzi dei farmaci rimborsati dal Servizio sanitario nazionale. 2019. Italian Ministry of Health & Italian Ministry of Economy and Finance. Accessed 23 November 23 2022. https:\/\/www.gazzettaufficiale.it\/eli\/id\/2020\/07\/24\/20A03810\/sg."},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511760716"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.931"},{"issue":"2","key":"e_1_3_3_33_1","first-page":"40","article-title":"Multinationals and Foreign Direct Investment: The Portuguese Experience (1900-2010)","volume":"1","author":"da Silva \u00c1. F.","year":"2016","unstructured":"da Silva, \u00c1. F. 2016. \u201cMultinationals and Foreign Direct Investment: The Portuguese Experience (1900-2010).\u201d Journal of Evolutionary Studies in Business 1 (2): 40\u201368.","journal-title":"Journal of Evolutionary Studies in Business"},{"key":"e_1_3_3_34_1","unstructured":"Dinis D. and H. F. Coelho. 2012. Resgatados: Os bastidores da ajuda financeira a Portugal. Esfera dos Livros."},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/0022002713499723"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1057\/cep.2014.43"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/13608749608539475"},{"key":"e_1_3_3_38_1","unstructured":"EFPIA. 2013. Warning: Austerity can Seriously Damage Your Health April 18. Accessed November 22 2022. https:\/\/www.efpia.eu\/news-events\/the-efpia-view\/blog-articles\/130418-warning-austerity-can-seriously-damage-your-health\/."},{"key":"e_1_3_3_39_1","unstructured":"European Commission. 2009. Pharmaceutical Sector Inquiry: Final Report. European Commission Competition DG."},{"key":"e_1_3_3_40_1","unstructured":"European Commission. 2011. Portugal: Memorandum of Understanding on specific economic policy conditionality. Accessed January 5 2023. https:\/\/ec.europa.eu\/economy_finance\/eu_borrower\/mou\/2011-05-18-mou-portugal_en.pdf."},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.72.5.468"},{"key":"e_1_3_3_42_1","first-page":"15","article-title":"Impact of the Economic Crisis in the Approval of new Oncological Drugs: The Portuguese Paradigm","volume":"9","author":"Fernandes I.","year":"2015","unstructured":"Fernandes, I., M. C. Rueff, S. Portela, and A. Mansinho. 2015. \u201cImpact of the Economic Crisis in the Approval of new Oncological Drugs: The Portuguese Paradigm.\u201d Impact of the Economic Crisis in the Approval of New Oncological Drugs: The Portuguese Paradigm 9: 15\u201318.","journal-title":"Impact of the Economic Crisis in the Approval of New Oncological Drugs: The Portuguese Paradigm"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.3138\/9781487529055"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/apce.12341"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/1077800405284363"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/03058298050330030501"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1515\/9781685853716"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.2202\/1469-3569.1214"},{"key":"e_1_3_3_49_1","unstructured":"Furlong A. S. A. Aarup and S. Horti. 2022. Who Killed the COVID Vaccine Waiver? Politico November 10. Accessed November 22 2022. https:\/\/www.politico.eu\/article\/covid-vaccine-poor-countries-waiver-killed\/."},{"key":"e_1_3_3_50_1","unstructured":"Gago A. and C. Moury. 2017. Making and Justifying Impossible Choices: Trade Unions and Three-Level Games in Ireland and Portugal. Paper presented at the Annual Conference of the Council of European Studies Glasgow."},{"key":"e_1_3_3_51_1","volume-title":"Affluence and Influence","author":"Gilens M.","year":"2012","unstructured":"Gilens, M. 2012. Affluence and Influence. In Affluence and Influence. Princeton University Press."},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.5639\/gabij.2019.0802.007"},{"key":"e_1_3_3_53_1","volume-title":"Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients","author":"Goldacre B.","year":"2014","unstructured":"Goldacre, B. 2014. Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients. Macmillan."},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/13501769608407037"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0047279417000095"},{"key":"e_1_3_3_56_1","unstructured":"House of Commons. 2005. The Influence of the Pharmaceutical Industry (Fourth Report of Session 2004\u201305). House of Commons Health Committee. Accessed on 23 November 2022. https:\/\/publications.parliament.uk\/pa\/cm200405\/cmselect\/cmhealth\/42\/42.pdf."},{"key":"e_1_3_3_57_1","unstructured":"INFARMED. 2016. Infarmed | Medicamentos Inovadores 2016. Infarmed. Accessed November 23 2022. https:\/\/www.sns.gov.pt\/noticias\/2017\/01\/16\/infarmed-medicamentos-inovadores-em-2016\/."},{"key":"e_1_3_3_58_1","doi-asserted-by":"crossref","unstructured":"Informant 10. 2017. Interview 10 December 28.","DOI":"10.22233\/20412495.1017.28"},{"key":"e_1_3_3_59_1","unstructured":"Informant 11. 2017. Interview 11 December 29."},{"key":"e_1_3_3_60_1","doi-asserted-by":"crossref","unstructured":"Informant 1. 2017. Interview 1 November 27.","DOI":"10.1145\/3158418"},{"key":"e_1_3_3_61_1","doi-asserted-by":"crossref","unstructured":"Informant 12. 2018. Interview 12 January 3.","DOI":"10.22233\/20412495.040118.12"},{"key":"e_1_3_3_62_1","unstructured":"Informant 13. 2018. Interview 13 January 4."},{"key":"e_1_3_3_63_1","doi-asserted-by":"crossref","unstructured":"Informant 14. 2018. Interview 14 January 4.","DOI":"10.12968\/sece.2018.11.14"},{"key":"e_1_3_3_64_1","unstructured":"Informant 15. 2018. Interview 15 January 5."},{"key":"e_1_3_3_65_1","doi-asserted-by":"crossref","unstructured":"Informant 16. 2018. Interview 16 January 8.","DOI":"10.4324\/9780429399107-2"},{"key":"e_1_3_3_66_1","doi-asserted-by":"crossref","unstructured":"Informant 17. 2018. Interview 17 January 10.","DOI":"10.32964\/TJ17.01"},{"key":"e_1_3_3_67_1","unstructured":"Informant 18. 2018. Interview 18 January 10."},{"key":"e_1_3_3_68_1","unstructured":"Informant 19. 2018. Interview 19 January 12."},{"key":"e_1_3_3_69_1","doi-asserted-by":"crossref","unstructured":"Informant 20. 2018. Interview 20 January 17.","DOI":"10.2307\/jj.399532.10"},{"key":"e_1_3_3_70_1","unstructured":"Informant 2. 2017. Interview 2 December 1."},{"key":"e_1_3_3_71_1","unstructured":"Informant 22. 2018. Interview 22 February 25."},{"key":"e_1_3_3_72_1","doi-asserted-by":"crossref","unstructured":"Informant 26. 2018. Interview 26 February 6.","DOI":"10.1002\/sfr.31020"},{"key":"e_1_3_3_73_1","unstructured":"Informant 27. 2018. Interview 27 February 9."},{"key":"e_1_3_3_74_1","doi-asserted-by":"crossref","unstructured":"Informant 28. 2018. Interview 28 February 21.","DOI":"10.1016\/j.whi.2017.09.007"},{"key":"e_1_3_3_75_1","doi-asserted-by":"crossref","unstructured":"Informant 29. 2018. Interview 29 February 21.","DOI":"10.18209\/iakle.2018.29..21"},{"key":"e_1_3_3_76_1","unstructured":"Informant 30. 2018. Interview 30 May 15."},{"key":"e_1_3_3_77_1","unstructured":"Informant 3. 2017. Interview 3 December 19."},{"key":"e_1_3_3_78_1","unstructured":"Informant 4. 2017. Interview 4 December 1."},{"key":"e_1_3_3_79_1","unstructured":"Informant 6. 2017. Interview 6 December 21."},{"key":"e_1_3_3_80_1","unstructured":"Informant 9. 2017. Interview 9 December 27."},{"key":"e_1_3_3_81_1","unstructured":"Jack A. 2011. Pfizer gets $800m boost for Lipitor. Financial Times July 10. Accessed November 23 2022. https:\/\/www.ft.com\/content\/6892b926-aae3-11e0-b4d8-00144feabdc0#axzz1mdwtwufL."},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/0952-1895.00192"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-019-01116-4"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1215\/03616878-10234184"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1080\/13501763.2016.1249013"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/hex.13013"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0143814X00010151"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1080\/13501763.2015.1008792"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1111\/polp.12076"},{"key":"e_1_3_3_90_1","doi-asserted-by":"crossref","unstructured":"Ladi S. C. Moury and F. Stolfi. 2022. Reputation and the Regulation of Pharmacies in Greece and Portugal. Council of European Studies June Lisbon.","DOI":"10.1017\/S0143814X23000363"},{"key":"e_1_3_3_91_1","unstructured":"Lei n.o 8\/2012 de 21 de fevereiro Assembleia da Rep\u00fablica. 2012."},{"key":"e_1_3_3_92_1","volume-title":"Politics and Markets","author":"Lindblom C. E.","year":"1977","unstructured":"Lindblom, C. E. 1977. Politics and Markets. Basic Books."},{"key":"e_1_3_3_93_1","doi-asserted-by":"crossref","unstructured":"Lisi M. R. Oliveira and J. Loureiro. 2021. Looking for Ariadne\u2019s thread: A systematic review on party-group relations in the last 20 years. Politics.","DOI":"10.1177\/02633957211030399"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-230-80257-5"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1080\/01402382.2019.1583482"},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1177\/0952076718796548"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0143814X00001239"},{"key":"e_1_3_3_98_1","unstructured":"Mancini S. 2020. Transparency Matters: Italy Moves Against the Secrecy Surrounding the Cost of Medicines. MSF Access Campaign \u2014 Medicines Are Not a Luxury September 23. Accessed November 22 2022. https:\/\/msf-access.medium.com\/transparency-matters-italy-moves-against-the-secrecy-surrounding-the-cost-of-medicines-4468a6e0ced6."},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1080\/13501763.2017.1336184"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1080\/00213624.1998.11506108"},{"key":"e_1_3_3_101_1","doi-asserted-by":"publisher","DOI":"10.1017\/jme.2021.8"},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.1177\/0261018310376805"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.1177\/0020731418822227"},{"key":"e_1_3_3_104_1","unstructured":"Moravcsik A. 1994. Why the European Community Strengthens the State: Domestic Politics and International Cooperation. Annual Meeting of the American Political Science Association New York."},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.1002\/hpm.816"},{"key":"e_1_3_3_106_1","doi-asserted-by":"publisher","DOI":"10.1080\/13608746.2019.1641945"},{"key":"e_1_3_3_107_1","doi-asserted-by":"publisher","DOI":"10.1080\/13608746.2019.1642622"},{"key":"e_1_3_3_108_1","doi-asserted-by":"publisher","DOI":"10.7765\/9781526149893"},{"key":"e_1_3_3_109_1","doi-asserted-by":"publisher","DOI":"10.7765\/9781526149893.00009"},{"key":"e_1_3_3_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6765.12190"},{"key":"e_1_3_3_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2020.02.014"},{"key":"e_1_3_3_112_1","doi-asserted-by":"publisher","DOI":"10.1787\/9789264266414-en"},{"key":"e_1_3_3_113_1","unstructured":"Or\u00e7amento do Estado para 2015 no. Lei n.o 82-B\/2014 Assembleia da Rep\u00fablica. 2014."},{"key":"e_1_3_3_114_1","volume-title":"Reforms at Risk","author":"Patashnik E. M.","year":"2014","unstructured":"Patashnik, E. M. 2014. \"Reforms at Risk.\" In Reforms at Risk. Princeton University Press."},{"key":"e_1_3_3_115_1","unstructured":"Pereira D. J. T. 2018. A Pol\u00edtica do medicamento e a troika: Entre constrangimentos internos e oportunidades externas [Universidade Nova de Lisboa]. Accessed November 23 2022. https:\/\/run.unl.pt\/handle\/10362\/58337."},{"key":"e_1_3_3_116_1","unstructured":"Pereira D. J. 2019. Estrat\u00e9gias de mobiliza\u00e7\u00e3o e a crise econ\u00f3mica: O caso da ind\u00fastria farmac\u00eautica. In Grupos de Interesse e Crise Econ\u00f3mica em Portugal 237\u2013263. 1st ed. Edi\u00e7\u00f5es S\u00edlabo."},{"key":"e_1_3_3_117_1","doi-asserted-by":"publisher","DOI":"10.1080\/13501760500160607"},{"key":"e_1_3_3_118_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-015-0182-5"},{"key":"e_1_3_3_119_1","unstructured":"Pires L. R. and N. Martins. 2015. Segredos de Estado. Editora Mat\u00e9ria-Prima."},{"key":"e_1_3_3_120_1","unstructured":"Portaria n.o 290-B\/2016 Minist\u00e9rio da Sa\u00fade. 2016."},{"key":"e_1_3_3_121_1","unstructured":"Portaria n.o 30-B\/2007 de 5 de janeiro Minist\u00e9rios da Economia e Inova\u00e7\u00e3o e da Sa\u00fade. 2007."},{"key":"e_1_3_3_122_1","unstructured":"Portaria n.o 618-A\/2005 de 27 de julho Minist\u00e9rios da Economia e Inova\u00e7\u00e3o e da Sa\u00fade. 2005."},{"key":"e_1_3_3_123_1","unstructured":"Protocolo com a Apifarma que define redu\u00e7\u00e3o na despesa do SNS com medicamentos hospitalares e de ambulat\u00f3rio. 2012. Governo de Portugal Minist\u00e9rio da Sa\u00fade. Accessed November 23 2022 https:\/\/www.portugal.gov.pt\/media\/601172\/20120514_ms_protocolo_apifarma.pdf."},{"key":"e_1_3_3_124_1","unstructured":"Randall W. 2007. Patent pendulum. Accessed November 23 2022. https:\/\/www.drugdiscoverynews.com\/patent-pendulum-1312."},{"key":"e_1_3_3_125_1","unstructured":"Relator Fernando Bento. 2015. Parecer do Conselho Consultivo da PGR sobre o Acordo bienal 2012\/2013 entre o Estado Portugu\u00eas e a Ind\u00fastria Farmac\u00eautica. Accessed November 23 2022. http:\/\/www.dgsi.pt\/pgrp.nsf\/7fc0bd52c6f5cd5a802568c0003fb410\/b713bb3b1390b37a80257ed7002f8b24?OpenDocument."},{"key":"e_1_3_3_126_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11558-017-9295-y"},{"key":"e_1_3_3_127_1","doi-asserted-by":"publisher","DOI":"10.1080\/09692290.2011.645848"},{"key":"e_1_3_3_128_1","doi-asserted-by":"publisher","DOI":"10.1017\/jme.2021.2"},{"key":"e_1_3_3_129_1","unstructured":"thepharmaletter. 2012. EFPIA President Warns that European Pricing Threatens Medicines Supply Flow June 26. Accessed November 22 2022. https:\/\/www.thepharmaletter.com\/article\/efpia-president-warns-that-european-pricing-threatens-medicines-supply-flow."},{"key":"e_1_3_3_130_1","doi-asserted-by":"crossref","unstructured":"Tompson W. and R. Price. 2009. The Political Economy of Reform: Lessons from Pensions Product Markets and Labour Markets in Ten OECD Countries. OECD.","DOI":"10.1787\/9789264073111-en"},{"key":"e_1_3_3_131_1","unstructured":"Treacy K. P. and N. Watson-Doig. 2016. What is Parallel Trade and How Does it Affect Pharma? Comp Law December 1. Accessed November 22 2022. https:\/\/knect365.com\/complaw-blog\/article\/073ed81f-0d17-4c0e-a819-38ff60332dec\/what-is-parallel-trade-and-how-does-it-affect-pharma."},{"key":"e_1_3_3_132_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-016-0056-8"},{"key":"e_1_3_3_133_1","volume-title":"The International and Domestic Politics of IMF Programs","author":"Vreeland J. R.","year":"2005","unstructured":"Vreeland, J. R. 2005. The International and Domestic Politics of IMF Programs. Yale University."},{"key":"e_1_3_3_134_1","doi-asserted-by":"publisher","DOI":"10.4337\/9781849807326"},{"key":"e_1_3_3_135_1","volume-title":"The Political Economy of Policy Reform","author":"Williamson J.","year":"1994","unstructured":"Williamson, J. 1994. The Political Economy of Policy Reform. Peterson Institute."},{"issue":"3","key":"e_1_3_3_136_1","first-page":"38","article-title":"Corporate Power Beyond Lobbying","volume":"3","author":"Woll C.","year":"2019","unstructured":"Woll, C. 2019. \u201cCorporate Power Beyond Lobbying.\u201d American Affairs 3 (3): 38\u201355.","journal-title":"American Affairs"},{"key":"e_1_3_3_137_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.18623"},{"key":"e_1_3_3_138_1","doi-asserted-by":"publisher","DOI":"10.1111\/rego.12098"}],"container-title":["Political Research Exchange"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/2474736X.2023.2193622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T09:37:01Z","timestamp":1729157821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/2474736X.2023.2193622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":137,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/2474736X.2023.2193622"],"URL":"https:\/\/doi.org\/10.1080\/2474736x.2023.2193622","relation":{},"ISSN":["2474-736X"],"issn-type":[{"type":"electronic","value":"2474-736X"}],"subject":[],"published":{"date-parts":[[2023,3,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=prxx20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=prxx20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-03-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2193622"}}